- Home
- BATL vs IVVD Comparison
BATL vs IVVD Comparison
Compare BATL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- IVVD
- Stock Information
- Founded
- BATL 1987
- IVVD 2020
- Country
- BATL United States
- IVVD United States
- Employees
- BATL N/A
- IVVD N/A
- Industry
- BATL Oil & Gas Production
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- BATL Energy
- IVVD Health Care
- Exchange
- BATL Nasdaq
- IVVD Nasdaq
- Market Cap
- BATL 109.4M
- IVVD 116.8M
- IPO Year
- BATL N/A
- IVVD 2021
- Fundamental
- Price
- BATL $2.76
- IVVD $0.47
- Analyst Decision
- BATL
- IVVD Strong Buy
- Analyst Count
- BATL 0
- IVVD 5
- Target Price
- BATL N/A
- IVVD $7.11
- AVG Volume (30 Days)
- BATL 67.9K
- IVVD 859.7K
- Earning Date
- BATL 11-12-2024
- IVVD 11-14-2024
- Dividend Yield
- BATL N/A
- IVVD N/A
- EPS Growth
- BATL N/A
- IVVD N/A
- EPS
- BATL N/A
- IVVD N/A
- Revenue
- BATL $191,482,000.00
- IVVD $11,564,000.00
- Revenue This Year
- BATL $2.21
- IVVD N/A
- Revenue Next Year
- BATL N/A
- IVVD $486.65
- P/E Ratio
- BATL N/A
- IVVD N/A
- Revenue Growth
- BATL N/A
- IVVD N/A
- 52 Week Low
- BATL $2.48
- IVVD $0.45
- 52 Week High
- BATL $9.69
- IVVD $5.20
- Technical
- Relative Strength Index (RSI)
- BATL 19.98
- IVVD 30.94
- Support Level
- BATL $2.75
- IVVD $0.57
- Resistance Level
- BATL $3.45
- IVVD $0.62
- Average True Range (ATR)
- BATL 0.15
- IVVD 0.06
- MACD
- BATL 0.04
- IVVD -0.01
- Stochastic Oscillator
- BATL 6.03
- IVVD 13.66
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent oil and gas producer operating exclusively in the Delaware Basin. It is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the United States. The company operates in one segment which focuses on oil and natural gas acquisition, production, exploration, and development.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.